Drug developer rattles tin for another cash dollop
MELBOURNE: Neurological diseases drug development company Actinogen Medical, capitalised at $95 million on the ASX,
MELBOURNE: Neurological diseases drug development company Actinogen Medical, capitalised at $95 million on the ASX,
FEATURED
Assisted living providers learn strategies to tackle staffing challenges
Senior living operators plan more moderate rental rate growth in 2026
Former city mortuary is now taking new senior residents
Best affordable housing design for Global Awards shortlisted
Planning authorities take wrecking ball to boomer projects
Best social housing community design for Global Awards shortlisted
INNOVATION
